Development of a vaccine for staphylococcal infections
Ended Project Grant Awarded Last action
- Award ID
- R41AI157087
- Recipient
-
Immunartes, LLC UEI ETMGB9KR3GG4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $767,533
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $509,690.90 Federal
- $257,842.00 Non-federal
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Description
- Abstract
- Staphylococcus aureus causes skin and soft tissue infections (ssti) that result in 14.2 million outpatient visits per year and 850,000 hospital admissions. S. Aureus infection is not associated with the development of immunity and, even with surgical and antibiotic therapy, recurrent infections occur frequently. Infections with antibiotic-resistant s. Aureus strains, designated mrsa (methicillin-resistant s. Aureus) are associated with poor disease outcomes and are now identified in 22% of hospital isolates. In order to address the public health crisis of mrsa, we are developing a vaccine to prevent invasive s. Aureus infections. Key features of s. Aureus disease are the pathogen's resistance to opsonophagocytic killing (OPK) and the suppression of the host's adaptive immune responses. Staphylococcal binding to immunoglobulin (IG) is mediated by staphylococcal protein a (SPA), a surface protein that associates with the FC-domain of IGG and the heavy chain of VH3 clan IGG and IGM. While the former activity provides protection from antibodies that induce OPK, the latter, through the crosslinking of IGM receptors, triggers proliferation and b cells and secretion of non- protective VH3 antibodies, thereby disrupting adaptive immune responses and the development of protective immunity. We have developed SPA*, a vaccine that elicits SPA-neutralizing antibodies that effectively promote OPK of the pathogen while also allowing the host to generate many different pathogen specific antibodies that together eliminate s. Aureus colonization and reduce the risk of invasive disease. This phase i sttr proposal aims to establish the feasibility of generating the SPA* vaccine by establishing its preclinical safety and biological efficacy.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$0 | $0 | |
| Amendment | -$0 | $0 | |
| Amendment | -$1,998 | $0 | |
| Amendment | -$1,998 | $0 | |
| Amendment | -$1,998 | $0 | |
| Amendment | $257,842 | $0 | |
| Original award | $257,842 | $257,842 |
Quick answers
Who received award R41AI157087?
R41AI157087 was awarded to Immunartes, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 16, 2021.
How much is award R41AI157087 worth?
$767,533 has been obligated on R41AI157087: $509,691 in federal funding and $257,842 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award